This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for Oxbryta®▼ (voxelotor) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
This section provides important information about Oxbryta®, including information from the Summary of Product Characteristics1
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The most common adverse reactions with Oxbryta® include:
In the event of hypersensitivity, discontinue Oxbryta® permanently and initiate medical therapy1
Contraindication: hypersensitivity to the active substance or to any of the excipients1
CYP, cytochrome P450; ESRD, end-stage renal disease; Hb, haemoglobin; HbA, adult haemoglobin; HbF, foetal haemoglobin; HbS, haemoglobin S; HbSS, sickle cell anaemia; HIV, human immunodeficiency virus; HPLC, high-performance liquid chromatography; MATE, multidrug and toxin extrusion protein; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; PI, Prescribing Information; PK, pharmacokinetics; SCD, sickle cell disease.
References:
What you need to know about Oxbryta® in clinical practice
The Oxbryta® team are here to support you with any queries
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024